ERBB2 and neoplasm: Most currently approved therapeutic Abs are antagonist that either directly bind to surface markers expressed on cancer cells like HER2, growth factors that support tumor growth like vascular endothelial growth factor, or regulatory proteins on cells like CTLA-4, PD-1 and PD-L1.